دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial
Tomasz J.GuzikMD, PhDabChinthanieRamasundarahettigeMSccdNanaPogosovaMD, PhDePatricioLopez-JaramilloMD, PhDfLeanneDyalBSc, MSccdScott D.BerkowitzMDgEvaMuehlhoferMD, PhDhDeepak L.BhattMD, MPHiKeith A.A.FoxMB, ChBjSalimYusufMD, DPhilcdJohn W.EikelboomMBBS, MSccd
doi : 10.1016/j.jacc.2020.11.061
Volume 77, Issue 5, 9 February 2021, Pages 511-525
Direct oral anticoagulants are administered in fixed doses irrespective of body weight, but guidelines recommend against their use in patients with extremes of body weight.
Dual Antithrombotic Therapy Targeting Residual Risk for Atherosclerotic Cardiovascular Disease: Does Body Mass Index Matter??
KarlynMartinMD, MSaSadiya S.KhanMD, MScbc
doi : 10.1016/j.jacc.2020.12.005
Volume 77, Issue 5, 9 February 2021, Pages 526-528
Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions
HideyukiKawashimaMDabKuniakiTakahashiMDaMasafumiOnoMDabHironoriHaraMDaRutaoWangMDbcChaoGaoMDbcFaisalSharifMD, PhDbMichael J.MackMDdDavid R.HolmesMDeMarie-ClaudeMoriceMDfStuart J.HeadMD, PhDgArie PieterKappeteinMD, PhDgDaniel J.F.M.ThuijsMDgMilanMilojevicMD, PhDghThiloNoackMDiFriedrich-WilhelmMohrMD, PhDiPiroze M.DavierwalaMDiPatrick W.SerruysMD, PhDbj…YoshinobuOnumaMD, PhDb
doi : 10.1016/j.jacc.2020.11.055
Volume 77, Issue 5, 9 February 2021, Pages 529-540
The long-term clinical benefit after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with total occlusions (TOs) and complex coronary artery disease has not yet been clarified.
Are All Total Occlusions Created Equal?: Striving for Complete Revascularization While Differentiating Apples From Oranges?
Jeffrey W.MosesMDMeghaPrasadMD, MS
doi : 10.1016/j.jacc.2020.12.008
Volume 77, Issue 5, 9 February 2021, Pages 541-543
Prospective Cohort Study of Infective Endocarditis in People Who Inject Drugs
Juan M.PericàsMD, PhD, MPHa?JaumeLlopisMD, PhDab?EugeneAthanMB, BS Honours, MPH, MDcMartaHern?ndez-MenesesMDaMargaret M.HannanMD, MRCPI, MRCPathdDavid R.MurdochMD, MSceZeinaKanafaniMD, MSfTomasFreibergerMD, PhDghJacobStrahilevitzMDiNuriaFern?ndez-HidalgoMD, MsC, PhDjCristianeLamasMRCP, PhDkEmanueleDurante-MangoniMD, PhDlPierreTattevinMD, PhDmFranciscoNacinovichMDnVivian H.ChuMD, MHSoJosé M.Mir?MD, PhDaInternational Collaboration on Endocarditis (ICE) Investigators?
doi : 10.1016/j.jacc.2020.11.062
Volume 77, Issue 5, 9 February 2021, Pages 544-555
Infective endocarditis (IE) in people who inject drugs (PWID) is an emergent public health problem.
Injection Drug Use: A Minor Criterion With Major Implications for Patients With Infective Endocarditis?
Larry M.BaddourMDaMartin H.ThornhillMBBS, BDS, PhDbMark J.DayerMBBS, PhDc
doi : 10.1016/j.jacc.2020.11.058
Volume 77, Issue 5, 9 February 2021, Pages 556-558
Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study
AlizaHussainMDaWenshengSunMSbcAnitaDeswalMD, MPHdJames A.de LemosMDeJohn W.McEvoyMB BCh MHSfRon C.HoogeveenPhDbcKunihiroMatsushitaMD, PhDfDavidAguilarMDgBiykemBozkurtMD, PhDahSalim S.ViraniMD, PhDabhAmil M.ShahMD, MPHiElizabethSelvinPhD, MPHfChiadiNdumuleMD, PhDfChristie M.BallantyneMDabcVijayNambiMD, PhDabch
doi : 10.1016/j.jacc.2020.11.063
Volume 77, Issue 5, 9 February 2021, Pages 559-571
Although intensive blood pressure reduction has cardiovascular benefits, the absolute benefit is greater in those at higher cardiovascular disease (CVD) risk.
Natriuretic Peptides as Predictors of Cardiovascular Events and All-Cause Mortality?
Martin A.AlpertMD
doi : 10.1016/j.jacc.2020.12.006
Volume 77, Issue 5, 9 February 2021, Pages 572-574
Local Pressure Drives Low-Density Lipoprotein Accumulation and Coronary Atherosclerosis in Hypertensive Minipigs
Rozh H.Al-MashhadiMD, PhDabcAhmed L.Al-MashhadiMDacZahra P.NasrMScaMartin B?dtkerMortensenMD, PhDacEsmeralda A.LewisMScdEmilioCamafeitaPhDdeKristianRavloMDaZheerAl-MashhadiMDafDaniel W.Kj?rMD, PhDgJohanPalmfeldtPhDaPeterBieMD, DMScihJesper M.JensenMD, PhDcBjarne L.N?rgaardMD, PhDcErlingFalkMD, DMSciacJes?sV?zquezPhDdeJacob F.BentzonMD, PhDacdf
doi : 10.1016/j.jacc.2020.11.059
Volume 77, Issue 5, 9 February 2021, Pages 575-589
The mechanisms by which hypertension accelerates coronary artery disease are poorly understood. Patients with hypertension often have confounding humoral changes, and to date, no experimental models have allowed analysis of the isolated effect of pressure on atherosclerosis in a setting that recapitulates the dimensions and biomechanics of human coronary arteries.
Systemic Arterial Hypertension: Innovative Methods to Elucidate Mechanisms of Atherosclerosis and Arterial Restructuring?
Peter H.StoneMDa
doi : 10.1016/j.jacc.2020.12.007
Volume 77, Issue 5, 9 February 2021, Pages 590-592
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids: JACC Focus Seminar
Richard L.WeinbergMD, PhDaRobert D.BrookMDbMelvynRubenfireMDaKim A.EagleMDa
doi : 10.1016/j.jacc.2020.11.060
Volume 77, Issue 5, 9 February 2021, Pages 593-608
Omega-3 polyunsaturated fatty acids (PUFAs) are a key component of a heart-healthy diet. For patients without clinical atherosclerotic cardiovascular disease, 2 or more servings of fatty fish per week is recommended to obtain adequate intake of omega-3 PUFAs. If this not possible, dietary supplementation with an appropriate fish oil may be reasonable. Supplementation with omega-3 PUFA capsules serves 2 distinct but overlapping roles: treatment of hypertriglyceridemia and prevention of cardiovascular events. Marine-derived omega-3 PUFAs reduce triglycerides and have pleiotropic effects including decreasing inflammation, improving plaque composition and stability, and altering cellular membranes. Clinical trial data have shown inconsistent results with omega-3 PUFAs improving cardiovascular outcomes. In this paper, the authors provide an overview of PUFAs and a summary of key clinical trial data. Recent trial data suggest the use of prescription eicosapentaenoic acid ethyl ester for atherosclerotic cardiovascular disease event reduction in selected populations.
Coenzyme Q10 for Patients With Cardiovascular Disease: JACC Focus Seminar
Albert E.RaiznerMDMiguel A.Qui?onesMD
doi : 10.1016/j.jacc.2020.12.009
Volume 77, Issue 5, 9 February 2021, Pages 609-619
Coenzyme Q10 (CoQ10) is a naturally occurring compound that is found in animals and all humans. It has a fundamental role in cellular energy production. Although it is produced in the body, tissue deficiency can occur due to medications such as statins, which inhibit the mevalonate pathway. The clinical syndromes of statin-associated muscle symptoms (SAMS) and some of the features observed in patients with heart failure (HF) may be related to blood and tissue deficiency of CoQ10. Numerous clinical trials of CoQ10 in SAMS have yielded conflicting results. Yet, the weight of evidence as reflected in meta-analyses supports the use of exogenous CoQ10 in SAMS. In patients with HF, large-scale randomized clinical trials are lacking, although one relatively contemporary trial, Q-SYMBIO, suggests an adjunctive role for CoQ10. The possibility that statin-related CoQ10 deficiency may play a role in patients with diastolic HF is an intriguing hypothesis that warrants further exploration.
Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar
Arrigo F.G.CiceroMD, PhDaFedericaFogacciMDcaAlbertoZambonMD, PhDb
doi : 10.1016/j.jacc.2020.11.056
Volume 77, Issue 5, 9 February 2021, Pages 620-628
The extracts of red yeast rice (RYR) are currently the most effective cholesterol-lowering nutraceuticals. This activity is mainly due to monacolin K, a weak reversible inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, whose daily consumption causes a reduction in low-density lipoprotein (LDL)-cholesterol plasma levels up to 15% to 25% within 6 to 8 weeks. The decrease in LDL-cholesterol is accompanied by a proportional decrease in total and non–high-density lipoprotein cholesterol, plasma apolipoprotein B, and high-sensitivity C-reactive protein. Some trials suggest that RYR use is associated with improvement in endothelial function and arterial stiffness, whereas a long-term study supports its role in the prevention of cardiovascular events. Despite the statin-like mechanism of action, the risk related to 3 to 10 mg monacolin K taken per day is minimal (mild myalgia in previously severely statin-intolerant subjects). RYR could represent a therapeutic tool to support lifestyle improvement in managing mild to moderate hypercholesterolemia in low-risk patients, including those who cannot be treated with statins or other LDL-cholesterol–lowering therapies.
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee
Dharam J.KumbhaniMD, SM, FACC(Chair, Writing Committee)Christopher P.CannonMD, FACC(Vice-Chair, Writing Committee)Craig J.BeaversPharmD, FACC(Writing Committee Member)Deepak L.BhattMD, MPH, FACC(Writing Committee Member)AdamCukerMD, MS(Writing Committee Member)Ty J.GluckmanMD, FACC(Writing Committee Member)Joseph E.MarineMD, FACC(Writing Committee Member)RoxanaMehranMD, FACC(Writing Committee Member)Steven R.MesseMD(Writing Committee Member)Nimesh S.PatelMD(Writing Committee Member)Benjamin E.PetersonMD, MPH(Writing Committee Member)KennethRosenfieldMD, FACC(Writing Committee Member)Sarah A.SpinlerPharmD, AACC(Writing Committee Member)Vinod H.ThouraniMD, FACC(Writing Committee Member)
doi : 10.1016/j.jacc.2020.09.011
Volume 77, Issue 5, 9 February 2021, Pages 629-658
2020: A Year to Remember—And From Which to Learn
AthenaPoppasMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2020.12.036
Volume 77, Issue 5, 9 February 2021, Pages 659-660
Variation in Cardiologist Statin Prescribing by Clinic Appointment Time
Allison H.OakesPhDSrinathAdusumalliMD, MScChristopher K.SniderMPHCharles A.L.RareshideMSMitesh S.PatelMD, MBA
doi : 10.1016/j.jacc.2020.11.057
Volume 77, Issue 5, 9 February 2021, Pages 661-662
Physical Activity–Related Left Ventricular Trabeculation: More Uncertainty Than Ever
AndrewD’SilvaMBBS, BSc, PhD
doi : 10.1016/j.jacc.2020.11.054
Volume 77, Issue 5, 9 February 2021, Pages 662-663
Reply: Physical Activity-Related Left Ventricular Trabeculation: More Uncertainty Than Ever
Jose A.de la ChicaMDInésGarc?a-LunarMD, PhDBelénOlivaMScValent?nFusterMD, PhDBorjaIb??ezMD, PhD
doi : 10.1016/j.jacc.2020.12.002
Volume 77, Issue 5, 9 February 2021, Pages 663-665
Surgical Explantation of Transcatheter Aortic Bioprostheses and Concurrent Other Cardiac Procedures
ShinichiFukuharaMDChan Tran N.NguyenBA
doi : 10.1016/j.jacc.2020.10.058
Volume 77, Issue 5, 9 February 2021, Pages 665-666
Reply: Surgical Explantation of Transcatheter Aortic Bioprostheses and Concurrent Other Cardiac Procedures
Sameer A.HirjiMD, MPHTsuyoshiKanekoMD
doi : 10.1016/j.jacc.2020.12.004
Volume 77, Issue 5, 9 February 2021, Page 666
